Psychemedics Releases First-Ever Education Insights Report: Uncovering Drug Trends in Educational Institutions Through Hair Testing

Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, is excited to announce the release of its first-ever Education Insights Report. This report provides an in-depth analysis of drug trends within educational institutions, shedding light on the growing challenges schools face in maintaining a drug-free environment for students and staff. ... Read more

Psychemedics Corporation Launches New Ketamine Hair Testing Service

Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing, is proud to announce the launch of its new ketamine hair testing solution. This innovative testing method marks a significant advancement in the detection and prevention for a drug-free workplace and community.  Ketamine, a powerful dissociative anesthetic and emerging drug of abuse, poses a growing ... Read more

Psychemedics Corporation’s Board of Directors Approves Plan to Terminate Registration of Its Common Stock

DALLAS, TX, August 12, 2024 – Psychemedics Corporation (Nasdaq:PMD) (“Psychemedics” or the “Company”) today announced that a Transaction Committee (the “Transaction Committee”) of the Board of Directors of the Company (the “Board”)  comprised of independent directors has recommended, and the Board has approved, a plan to cease the registration of the Company’s common stock under ... Read more

Psychemedics Recognized as a Top 10 Employee Health Testing Services Provider

Dallas, TX – March 21, 2024 Psychemedics Corporation (NASDAQ: PMD), a global leader in drug testing using hair analysis, is proud to announce its recognition as one of the Top 10 Employee Health Testing Services Providers for 2024 by ManageHR. This prestigious accolade highlights Psychemedics’ commitment to excellence and innovation in the field of employee ... Read more

Psychemedics Corporation Announces Relocation of Headquarters to Dallas, Texas

ACTON, Mass., January 2, 2024 Psychemedics Corporation, a global leader in hair testing for drugs of abuse, proudly announces the relocation of its corporate headquarters from Acton, Massachusetts, to Dallas, Texas, while reaffirming its unwavering dedication to delivering exceptional service and maintaining the highest standards in hair drug testing. The move to Dallas underscores Psychemedics’ ... Read more

Psychemedics Corporation Appoints Daniella Mehalik as VP – Finance

ACTON, Mass., Nov. 27, 2023 -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for directing and managing all financial activities at Psychemedics, including comprehensive oversight of ... Read more

Unveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug Screen

ACTON, Mass., Oct. 27, 2023 -- In an era marked by relentless change and the pressing need to adapt, Psychemedics, a pioneer in the drug screening industry, proudly announces the launch of a revolutionary, Advanced 5-Panel Drug Screen. This groundbreaking offering will transform the way organizations safeguard their workplaces, shifting the spotlight from marijuana to ... Read more

Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer

Acton, MA – [September 21, 2023] Psychemedics Corporation, the world’s largest provider of hair testing for drugs of abuse, is pleased to announce the appointment of Shannon Shoemaker as its new Chief Revenue Officer. In this role, Shoemaker will be responsible for overseeing the company's revenue generation and growth strategies. With an exceptional track record ... Read more

Psychemedics Corporation Welcomes Drew Reynolds To Its Board Of Directors And Announces The Retirement Of Harry Connick From His Director Role

Acton, Massachusetts, March 22, 2022 – Psychemedics Corporation (NASDAQ:PMD), the world’s largest provider of hair testing for drugs of abuse, is pleased to welcome Andrew “Drew” M. Reynolds to the Psychemedics Board of Directors effective April 4th,2022.  Mr. Reynolds will also serve as a member of the Audit, Compensation, and Nominating and Governance Committees. Mr. ... Read more

Sarah Ashby Rejoins Psychemedics Corporation as Vice President, General Counsel

ACTON, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Sarah Ashby has rejoined the company as Vice President, General Counsel. In this important role, Sarah will be responsible for directing and managing all of the company’s legal activities. She will report directly to the company’s CEO. Sarah rejoins Psychemedics from ... Read more